Federal award (DEFINITIVE CONTRACT, fiscal year 2024)
Recipient: MAPP BIOPHARMACEUTICAL, INC.
Awarding agency: Department of Health and Human Services / Office of Assistant Secretary for Preparedness and Response
Funding agency: Department of Health and Human Services / Office of Assistant Secretary for Preparedness and Response
Period of performance: 2024-03-20 to 2032-12-31
Current total value of award: $3004498.02
Description: THE PURPOSE OF THE UNILATERAL NO COST MODIFICATION IS TO DESIGNATE THE ALTERNATE COR DR. SAIMA ZAMAN AS THE PRIMARY COR IAW THE EXECUTED COR DESIGNATION MEMORANDUM. DR. CAROL DIAZ-DIAZ WILL ASSUME THE POSITION OF ALTERNATE COR.